Literature DB >> 17006606

A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population.

Sanae Kabata Ikehara1,2, Yuzuru Ikehara3, Keitaro Matsuo2, Kaoru Hirose2, Toru Niwa4, Hidemi Ito2, Seiji Ito5, Yasuhiro Kodera6, Yoshitaka Yamamura5, Hayao Nakanishi4, Masae Tatematsu4, Kazuo Tajima1,2.   

Abstract

Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription. The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling. Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms. A case-control study was conducted on incident gastric adenocarcinoma patients (n=271) and age-gender frequency-matched control subjects (n=271). We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94). Neither IL1B-31, -511 nor FAS-670 polymorphisms showed significantly different risks of gastric adenocarcinoma. Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019). In particular, subjects with stage IV had a two times higher probability of having either IL1B-31TT (or IL1B-511CC) genotype compared with stage I subjects. These observations suggest that IL1B-31TT and IL1B-511CC are associated with disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006606     DOI: 10.1007/s10038-006-0040-2

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  40 in total

Review 1.  The IKK/NF-kappa B pathway.

Authors:  Uwe Senftleben; Michael Karin
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

Review 2.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity.

Authors:  Giuseppina Bonizzi; Michael Karin
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

3.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.

Authors:  N Sasaki; T Morisaki; K Hashizume; T Yao; M Tsuneyoshi; H Noshiro; K Nakamura; T Yamanaka; A Uchiyama; M Tanaka; M Katano
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 4.  Helicobacter pylori and gastrointestinal tract adenocarcinomas.

Authors:  Richard M Peek; Martin J Blaser
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

5.  Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.

Authors:  M Osaki; S Kase; I Kodani; M Watanabe; H Adachi; H Ito
Journal:  Gastric Cancer       Date:  2001       Impact factor: 7.370

6.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer.

Authors:  E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

7.  Relationship between IL-1beta gene polymorphism and gastric mucosal IL-1beta levels in patients with Helicobacter pylori infection.

Authors:  Jiang Xuan; Ryuzo Deguchi; Sumio Watanabe; Hideki Ozawa; Tetsuya Urano; Yoshiaki Ogawa; Ryuki Fukuda; Hiroshi Kijima; Yasuhiro Koga; Atsushi Takagi
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

8.  Gene-environment Interactions and Polymorphism Studies of Cancer Risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II).

Authors:  Nobuyuki Hamajima; Keitaro Matsuo; Toshiko Saito; Kaoru Hirose; Manami Inoue; Toshiro Takezaki; Tetsuo Kuroishi; Kazuo Tajima
Journal:  Asian Pac J Cancer Prev       Date:  2001

9.  Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.

Authors:  Emad M El-Omar; Charles S Rabkin; Marilie D Gammon; Thomas L Vaughan; Harvey A Risch; Janet B Schoenberg; Janet L Stanford; Susan T Mayne; James Goedert; William J Blot; Joseph F Fraumeni; Wong-Ho Chow
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

10.  A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma.

Authors:  José Carlos Machado; Céu Figueiredo; Paulo Canedo; Paul Pharoah; Ralph Carvalho; Sérgio Nabais; Catarina Castro Alves; Maria Luisa Campos; Leen-Jan Van Doorn; Carlos Caldas; Raquel Seruca; Fátima Carneiro; Manuel Sobrinho-Simões
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

View more
  9 in total

1.  Associations of three common polymorphisms in CD95 and CD95L promoter regions with gastric cancer risk.

Authors:  Fan Li; Yuliang Liu; Tao Fu; Weidong Tong; Anping Zhang
Journal:  Tumour Biol       Date:  2013-05-17

2.  Effects of the interleukin-1β-511 C/T gene polymorphism on the risk of gastric cancer in the context of the relationship between race and H. pylori infection: a meta-analysis of 20,000 subjects.

Authors:  Min-Jeong Park; Myung-Han Hyun; Jong-Pill Yang; Jeong-Min Yoon; Sungsoo Park
Journal:  Mol Biol Rep       Date:  2014-09-26       Impact factor: 2.316

3.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

4.  Interleukin-1 beta single-nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer in Helicobacter pylori-infected Peruvians.

Authors:  Sebastian Gehmert; Billie Velapatiño; Phabiola Herrera; Jaqueline Balqui; Livia Santivañez; Jaime Cok; Gloria Vargas; Juan Combe; Douglas J Passaro; Sijin Wen; Frank Meyer; Douglas E Berg; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

Review 5.  Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk.

Authors:  Jiali Xu; Zhiqiang Yin; Songyu Cao; Wen Gao; Lingxiang Liu; Yongmei Yin; Ping Liu; Yongqian Shu
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

6.  CD95 rs1800682A/G variant and tumor risk in Asians: evidence from a meta-analysis of 36 case-control studies containing 22,438 samples.

Authors:  Cheng Jin; Xiaomin Wu; Yuanlong Gu; Fenglai Yuan; Qinghai Ye; Feng Dai; Lijie Zhu; Yuanyuan Mi
Journal:  Med Sci Monit       Date:  2015-02-27

Review 7.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

Review 8.  Helicobacter pylori Infection Synergistic with IL-1β Gene Polymorphisms Potentially Contributes to the Carcinogenesis of Gastric Cancer.

Authors:  Jun-Bo Hong; Wei Zuo; An-Jiang Wang; Nong-Hua Lu
Journal:  Int J Med Sci       Date:  2016-04-08       Impact factor: 3.738

9.  Interleukin-1B 31 C>T polymorphism combined with Helicobacter pylori-modified gastric cancer susceptibility: evidence from 37 studies.

Authors:  Hua-Yong Ying; Bei-Wei Yu; Zong Yang; Shan-Shan Yang; Li-Hong Bo; Xiao-Yun Shan; Hui-Jiao Wang; Yi-Jun Zhu; Xue-Song Wu
Journal:  J Cell Mol Med       Date:  2016-01-25       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.